Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.08
HSKA's Cash to Debt is ranked higher than
66% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. HSKA: 2.08 )
HSKA' s 10-Year Cash to Debt Range
Min: 0.27   Max: No Debt
Current: 2.08

Equity to Asset 0.53
HSKA's Equity to Asset is ranked higher than
66% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. HSKA: 0.53 )
HSKA' s 10-Year Equity to Asset Range
Min: 0.02   Max: 0.78
Current: 0.53

0.02
0.78
F-Score: 7
Z-Score: -0.18
M-Score: -2.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 4.30
HSKA's Operating margin (%) is ranked higher than
83% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. HSKA: 4.30 )
HSKA' s 10-Year Operating margin (%) Range
Min: -125.26   Max: 6.71
Current: 4.3

-125.26
6.71
Net-margin (%) 3.16
HSKA's Net-margin (%) is ranked higher than
83% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -69.57 vs. HSKA: 3.16 )
HSKA' s 10-Year Net-margin (%) Range
Min: -132.76   Max: 42.28
Current: 3.16

-132.76
42.28
ROE (%) 5.64
HSKA's ROE (%) is ranked higher than
87% of the 877 Companies
in the Global Biotechnology industry.

( Industry Median: -28.59 vs. HSKA: 5.64 )
HSKA' s 10-Year ROE (%) Range
Min: -104.28   Max: 140.27
Current: 5.64

-104.28
140.27
ROA (%) 2.89
HSKA's ROA (%) is ranked higher than
86% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. HSKA: 2.89 )
HSKA' s 10-Year ROA (%) Range
Min: -69.96   Max: 61.02
Current: 2.89

-69.96
61.02
ROC (Joel Greenblatt) (%) 16.56
HSKA's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. HSKA: 16.56 )
HSKA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -176.87   Max: 22.95
Current: 16.56

-176.87
22.95
Revenue Growth (%) 3.00
HSKA's Revenue Growth (%) is ranked higher than
79% of the 646 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. HSKA: 3.00 )
HSKA' s 10-Year Revenue Growth (%) Range
Min: -16.9   Max: 10.4
Current: 3

-16.9
10.4
EBITDA Growth (%) -24.60
HSKA's EBITDA Growth (%) is ranked higher than
63% of the 621 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. HSKA: -24.60 )
HSKA' s 10-Year EBITDA Growth (%) Range
Min: -63.9   Max: 27.7
Current: -24.6

-63.9
27.7
» HSKA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

HSKA Guru Trades in Q3 2013

Jim Simons 81,780 sh (+10.1%)
Mario Gabelli 60,435 sh (-5.77%)
» More
Q4 2013

HSKA Guru Trades in Q4 2013

Mario Gabelli 61,935 sh (+2.48%)
Jim Simons 70,380 sh (-13.94%)
» More
Q1 2014

HSKA Guru Trades in Q1 2014

Mario Gabelli 59,935 sh (-3.23%)
Jim Simons 55,880 sh (-20.6%)
» More
Q2 2014

HSKA Guru Trades in Q2 2014

Jim Simons 65,980 sh (+18.07%)
Mario Gabelli 58,000 sh (-3.23%)
» More
» Details

Insider Trades

Latest Guru Trades with HSKA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2012-12-31 Add 29.08%$7.96 - $9.54 $ 12.8147%62135
Mario Gabelli 2012-09-30 Add 50.73%$7.78 - $11.3 $ 12.8136%48135
Mario Gabelli 2012-06-30 Add 56.54%$10.9 - $12.85 $ 12.818%31935
Mario Gabelli 2011-06-30 Add 31.85%$6.12 - $9.96 $ 12.8157%20700
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 29.00
HSKA's P/E(ttm) is ranked higher than
93% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HSKA: 29.00 )
HSKA' s 10-Year P/E(ttm) Range
Min: 0.5   Max: 549.09
Current: 29

0.5
549.09
P/B 1.54
HSKA's P/B is ranked higher than
94% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. HSKA: 1.54 )
HSKA' s 10-Year P/B Range
Min: 0.22   Max: 75.45
Current: 1.54

0.22
75.45
P/S 0.91
HSKA's P/S is ranked higher than
98% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 20.06 vs. HSKA: 0.91 )
HSKA' s 10-Year P/S Range
Min: 0.12   Max: 2.24
Current: 0.91

0.12
2.24
PFCF 427.00
HSKA's PFCF is ranked higher than
89% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HSKA: 427.00 )
HSKA' s 10-Year PFCF Range
Min: 2.45   Max: 463
Current: 427

2.45
463
EV-to-EBIT 25.12
HSKA's EV-to-EBIT is ranked higher than
92% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HSKA: 25.12 )
HSKA' s 10-Year EV-to-EBIT Range
Min: 4.8   Max: 164.2
Current: 25.12

4.8
164.2
Shiller P/E 97.85
HSKA's Shiller P/E is ranked higher than
93% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HSKA: 97.85 )
HSKA' s 10-Year Shiller P/E Range
Min: 1.88   Max: 106.85
Current: 97.85

1.88
106.85
Current Ratio 2.08
HSKA's Current Ratio is ranked higher than
62% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. HSKA: 2.08 )
HSKA' s 10-Year Current Ratio Range
Min: 1.03   Max: 5.19
Current: 2.08

1.03
5.19
Quick Ratio 1.33
HSKA's Quick Ratio is ranked higher than
59% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. HSKA: 1.33 )
HSKA' s 10-Year Quick Ratio Range
Min: 0.56   Max: 4.4
Current: 1.33

0.56
4.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.00
HSKA's Dividend Yield is ranked lower than
55% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. HSKA: 1.00 )
HSKA' s 10-Year Dividend Yield Range
Min: 0.79   Max: 3.71
Current: 1

0.79
3.71
Yield on cost (5-Year) 1.00
HSKA's Yield on cost (5-Year) is ranked lower than
60% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. HSKA: 1.00 )
HSKA' s 10-Year Yield on cost (5-Year) Range
Min: 0.79   Max: 3.71
Current: 1

0.79
3.71
Share Buyback Rate -3.10
HSKA's Share Buyback Rate is ranked higher than
87% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. HSKA: -3.10 )
HSKA' s 10-Year Share Buyback Rate Range
Min: 1.8   Max: -29.6
Current: -3.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.64
HSKA's Price/Tangible Book is ranked higher than
89% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 8.73 vs. HSKA: 2.64 )
HSKA' s 10-Year Price/Tangible Book Range
Min: 0.3   Max: 261.43
Current: 2.64

0.3
261.43
Price/DCF (Projected) 1.41
HSKA's Price/DCF (Projected) is ranked higher than
98% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HSKA: 1.41 )
HSKA' s 10-Year Price/DCF (Projected) Range
Min: 0.57   Max: 20.11
Current: 1.41

0.57
20.11
Price/Median PS Value 1.29
HSKA's Price/Median PS Value is ranked higher than
77% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. HSKA: 1.29 )
HSKA' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 18.7
Current: 1.29

0.23
18.7
Price/Graham Number 1.73
HSKA's Price/Graham Number is ranked higher than
96% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HSKA: 1.73 )
HSKA' s 10-Year Price/Graham Number Range
Min: 0.19   Max: 26.4
Current: 1.73

0.19
26.4
Earnings Yield (Greenblatt) 4.00
HSKA's Earnings Yield (Greenblatt) is ranked higher than
72% of the 475 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. HSKA: 4.00 )
HSKA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 20.7
Current: 4

0.6
20.7
Forward Rate of Return (Yacktman) 2.58
HSKA's Forward Rate of Return (Yacktman) is ranked higher than
92% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -10.16 vs. HSKA: 2.58 )
HSKA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -17.2   Max: 9.1
Current: 2.58

-17.2
9.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Heska Corporation was founded as Paravax, Inc. in 1988 and conducted research on vaccines to prevent infections by parasites. It was originally incorporated in California in 1988, and it subsequently incorporated in Delaware in 1997. It develops, manufactures, markets, sells and supports veterinary products. The Company's core focus is on the canine and feline companion animal health markets where it strives to provide high value products. The Company's business is comprised of two reportable segments, Core Companion Animal Health and other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment ('CCA') includes diagnostic instruments and supplies as well as single use diagnostic and other tests, vaccines and pharmaceuticals, mainly for canine and feline use. These products are sold directly by it as well as through independent third-party distributors and other distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment ('OVP') includes private label vaccine and pharmaceutical production, mainly for cattle but also for other animals including small mammals and fish. All OVP products are sold by third parties under third party labels. The Company presently sells a variety of companion animal health products and services, among the most significant of which are the following: veterinary instruments; point-of-care diagnostic and other tests; veterinary diagnostic laboratory products and services; pharmaceuticals and supplements; vaccines and other biologicals. It offers a line of veterinary diagnostic and other instruments. Its line of veterinary instruments includes the following: Blood Chemistry; Hematology; Blood Gases; and IV Pumps. The DRI-CHEM 4000 Veterinary Chemistry Analyzer is a robust system that uses dry slide technology for blood chemistry and electrolyte analysis and has the ability to run 22 tests at a time with a single blood sample. The HEMATRUE Veterinary Hematology Analyzer is an easy-to-use blood analyzer that measures such key parameters as white blood cell count, red blood cell count, platelet count and hemoglobin levels in animals. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. Renal damage is a cause of death in both dogs and cats. Several inflammatory, infectious or neoplastic diseases can damage an animal's kidneys. Allergy is common in companion animals, and it has been estimated to affect approximately 10% to 15% of dogs. The Company sells kits to conduct blood testing using its ALLERCEPT Definitive Allergen Panels to third-party veterinary diagnostic laboratories outside of the United States. It has veterinary diagnostic laboratories i
» More Articles for HSKA

Headlines

Articles On GuruFocus.com
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
Heska Corporation: Strong Balance Sheet and Dividend Yield Do Not Compensate for Difficult Business Dec 13 2012 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 5,000 Shares Jun 01 2010 
Heska Corp. (HSKA) CEO Robert B Grieve buys 6,500 Shares May 21 2010 
Weekly CFO Buys Highlight: ZixIt, Global Defense Technology and Systems, FelCor Lodging Trust, Heska Mar 07 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 1,000 Shares Mar 01 2010 
Weekly CFO Buys Highlight: Heska Corp., Apollo Investment Corp., EXACT Sciences Corp., Innospec Inc. Feb 28 2010 
Heska Corp. (HSKA) President and COO Michael J Mcginley buys 12,290 Shares Feb 26 2010 


More From Other Websites
Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% Sep 29 2014
Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% Sep 26 2014
Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher Sep 22 2014
Alder Biopharmaceuticals (ALDR) in Focus: Stock Up 5.2% Sep 18 2014
Dendreon (DNDN) in Focus: Stock Up 9.4% Sep 16 2014
Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% Sep 11 2014
HESKA CORP Financials Aug 19 2014
HESKA CORP Files SEC form 10-Q, Quarterly Report Aug 05 2014
Heska (HSKA) Shares March Higher, Can It Continue? Aug 01 2014
HESKA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 30 2014
Heska Reports 25.5% Revenue Growth, $0.17 Per Share vs. $(0.38), for the Second Quarter of 2014 Jul 30 2014
Heska (HSKA) Jumps: Stock Adds 5.89% in Session Jul 28 2014
Webcast Alert: Heska Announces Second Quarter 2014 Earnings Conference Call Webcast Jul 16 2014
Stifel to hold a conference May 28 2014
Heska Corporation to Present at the Stifel Dental & Veterinary Conference 2014 May 27 2014
B. Riley to hold a conference May 19 2014
Heska Corporation to Present at the 15th Annual B. Riley Investor Conference May 16 2014
Heska Corporation (HSKA) CEO Kevin Wilson on Q1 2014 Results - Earnings Call Transcript May 11 2014
HESKA CORP Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements... May 08 2014
HESKA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK